currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the ...
“The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber’s remarkable leadership,” said ...
currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the ...
CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly ...
Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...
Takeda has been restructured under new CEO Christophe Weber, who took over in 2014 and has focused the company on cancer and specialist gastrointestinal drugs, and early stage central nervous ...
Although the timing of tariffs is uncertain, we believe that it is likely that Trump will not want to wait two to three years ...
The Japanese pharma company acquired Ariad a year ago for $5.2bn, and the latest, more modest acquisition, shows that Takeda's chief Christophe Weber sees buy-outs as ongoing route to growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results